Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Jan 26, 2021 9:45 AM - Jan 28, 2021 5:00 PM

(US Eastern Standard Time)

Pharmacovigilance and Risk Management Strategies Conference

Session 7: Artificial Intelligence and Natural Language Processing: Offering True Benefits to PV Organizations Today

Session Chair(s)

Mariette  Boerstoel-Streefland, MD, MBA, MS

Mariette Boerstoel-Streefland, MD, MBA, MS

Senior Vice President, Patient Safety Officer , Bristol Myers Squibb, United States

Lisa Melanie Harinstein, PHARMD

Lisa Melanie Harinstein, PHARMD

Team Leader, Division of Pharmacovigilance, FDA, FDA, United States

Annette S. Williams, MBA, RPH

Annette S. Williams, MBA, RPH

Vice President, Pharmacovigilance, IQVIA, United States

Life science companies are actively pursuing automated solutions to address the challenge of managing increasing volumes of safety-related data from a myriad of sources, as well as to help identify, extract and interpret data for improved pharmacovigilance (PV). Assessing technology tools – such as robotic process automation (RPA), and natural language processing (NLP) has become more commonplace. This session will focus on specific use cases across the pharmacovigilance continuum. It will showcase how AI/NLP is being applied to increase robustness and efficiency for AE case intake from various territories across the globe. We will explore how NLP is now being employed to identify patients at risk in clinical trials as well as develop safety-related intelligence landscapes from scientific literature, internal preclinical and clinical safety reports that can be used to contextualize potential safety signals, as well as how regulatory agencies are utilizing the technology for pharmacovigilance.

Learning Objective :
  • Define AI, RPA, and NLP and its application
  • Outline how pharma organizations are using NLP for safety applications; including limitations and validation
  • What is the current situation; where are various stakeholders in their use of AI
  • Understand effective utilization of AI and NLP for intake of AE information from various territories worldwide
  • List how the FDA is applying AI to pharmacovigilance strategies.

Speaker(s)

Mariette  Boerstoel-Streefland, MD, MBA, MS

Mariette Boerstoel-Streefland, MD, MBA, MS

Senior Vice President, Patient Safety Officer , Bristol Myers Squibb, United States

Global Intake Using NLP, Translation, AI in an Ever-changing PV Organization part 1

François  Audibert, MSC

François Audibert, MSC

Vice President – U.S. Operations, Vitrana, United States

Global Intake Using NLP, Translation, AI in an Ever-Changing PV Organization part 2

Jane  Reed, PHD

Jane Reed, PHD

Director, Life Science, Linguamatics, United Kingdom

New Uses of Natural Language Processing (NLP) in Product Safety

Oanh  Dang, PHARMD

Oanh Dang, PHARMD

Pharmacotherapy Specialist, Regulatory Science Staff, OSE, CDER, FDA, United States

Leveraging Applied AI Within Pharmacovigilance

Allan  Fong, MS

Allan Fong, MS

Research Scientist and Data Scientist, Medstar Health National Center For Human Factors In Healthcare, United States

Patient Safety Monitoring using NLP and Machine Learning: A Healthcare Perspective

Aaron Zachary Hettinger, MD, MS

Aaron Zachary Hettinger, MD, MS

Director of Cognitive Informatics, Medstar Health National Center For Human Factors In Healthcare, United States

Speaker

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.